MOTS-c Peptide Protects Brain from Sepsis Injury by Fortifying Blood-Brain Barrier
Background
Sepsis, a life-threatening response to infection, frequently leads to severe complications including sepsis-associated encephalopathy and acute brain injury. This damage is often linked to the breakdown of the blood-brain barrier (BBB), a critical protective shield that regulates substance entry into the brain. While the importance of BBB integrity is recognized, effective therapeutic strategies specifically targeting BBB protection to mitigate sepsis-induced brain injury remain elusive.
Results
The study revealed that MOTS-c treatment significantly attenuated brain injury in the sepsis model. Specifically, MOTS-c reduced neuronal apoptosis by 43% (p<0.001) and decreased the expression of the astrocyte activation marker GFAP by 35% (p<0.01) compared to the LPS-only group. Furthermore, MOTS-c treatment dramatically improved the integrity of the blood-brain barrier, evidenced by a 2.1-fold increase in the tight junction protein ZO-1 and a 1.8-fold increase in occludin expression (p<0.001 for both). This was accompanied by a significant reduction in inflammatory cytokines, with TNF-α levels decreasing by 40% and IL-6 by 30% (p<0.001). Ultrastructural analysis confirmed that MOTS-c preserved the tight junctions and overall integrity of the blood-brain barrier, preventing leakage. The most critical finding was that MOTS-c directly strengthened the blood-brain barrier's ultrastructure, which was identified as a key mechanism underlying its neuroprotective effects against LPS-induced sepsis.
Why It Matters
This research highlights MOTS-c as a promising therapeutic candidate for mitigating sepsis-associated brain injury by directly targeting the blood-brain barrier. The ability of MOTS-c to preserve BBB integrity and reduce neuroinflammation offers a novel strategy for protecting the brain during severe systemic infections. These findings could pave the way for developing new pharmacological interventions to prevent neurological complications in critically ill patients with sepsis. Future research should focus on further elucidating the precise molecular pathways involved and progressing towards preclinical safety and efficacy studies in larger animal models, potentially leading to human clinical trials.